Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
March 25, 2019

Thermo Fisher Scientific to buy viral vector CDMO Brammer Bio for $1.7bn

Thermo Fisher Scientific has agreed to acquire viral vector contract development and manufacturing organization (CDMO), Brammer Bio, for around $1.7bn in cash.

Image: Thermo Fisher Scientific has agreed to acquire Brammer Bio. Photo: courtesy of Thermo Fisher Scientific Inc.